Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + XELOX Neoadjuvant Therapy in GI Tumors
NCT05515796Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, rectal adenocarcinoma. Started Sep 2022; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on NCT05515796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05515796.